Icon to buy division of Cross Country Healthcare

February 4, 2013 by The Associated Press

Icon PLC plans to buy the clinical trial services division of Cross Country Healthcare Inc. in a deal potentially worth more than $55 million, as the Irish company seeks to grow globally and improve its drug safety consulting.

Icon, which is based in Dublin, said Monday it will pay $52 million in cash for the division plus an additional $3.75 million if some performance-based milestones are reached. It expects the deal to close within the next 30 days.

Icon provides development services to and medical device makers. Cross Country's clinical trial services division provides contract staffing and permanent placement services as well as work.

Cross Country, based in Boca Raton, Florida, said the clinical trial services business has been a "meaningful contributor" to the company for more than a decade. The company said it decided to sell it as part of a move to narrow its focus and focus on its resources on its and physician staffing businesses.

Cross Country Healthcare shares finished at $5.60 on Friday. That is nearer their 52-week high of $6.72 set last February. Its shares hit a low of $3.80 on mid-November.

Explore further: Pfizer will buy NextWave Pharma for up to $700M


Related Stories

Pfizer will buy NextWave Pharma for up to $700M

October 22, 2012

(AP)—Pfizer said Monday it will buy NextWave Pharmaceuticals Inc., a company that makes a liquid attention deficit hyperactivity disorder drug, in a deal worth as much as $700 million.

Recommended for you

Sustaining biomedical research: Med school deans speak out

May 27, 2015

Cuts in federal support and unreliable funding streams are creating a hostile work environment for scientists, jeopardizing the future of research efforts and ultimately clinical medicine, according to leaders of the nation's ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.